Cerebrolysin®: a guide to its use in dementia

    This is a preview of subscription content, log in to check access.

    Table I
    Table II

    References

    1. 1.

      Plosker GL, Gauthier S. Cerebrolysin: a review of its use in dementia. Drugs Aging 2009; 26(11): 893–915

      PubMed  Article  CAS  Google Scholar 

    2. 2.

      Cerebrolysin® solution for injection: summary of product characteristics. Unterach, Austria: Ever Neuro Pharma GmbH, 2009 Dec

      Google Scholar 

    3. 3.

      Bae C-Y, Cho C-Y, Cho K, et al. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer’s disease. J Am Geriatr Soc 2000 Dec; 48(12): 1566–71

      PubMed  CAS  Google Scholar 

    4. 4.

      Panisset M, Gauthier S, Moessler H, et al. Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. J Neural Transm 2002 Jul; 109(7–8): 1089–1104

      PubMed  Article  CAS  Google Scholar 

    5. 5.

      Ruether E, Husmann R, Kinzler E, et al. A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Int Clin Psychopharmacol 2001 Sep; 16(5): 253–63

      PubMed  Article  CAS  Google Scholar 

    6. 6.

      Alvarez XA, Cacabelos R, Laredo M, et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Eur J Neurol 2006 Jan; 13(1): 43–54

      PubMed  Article  CAS  Google Scholar 

    7. 7.

      Alvarez XA, Cacabelos R, Sampedro C, et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurol. Epub 2010 May 25

    8. 8.

      Ruether E, Alvarez XA, Rainer M, et al. Sustained improvement of cognition and global function in patients with moderately severe Alzheimer’s disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin®. J Neural Transm 2002; 62 Suppl.: 265–75

      CAS  Google Scholar 

    9. 9.

      Alvarez A, Cacabelos R, Aleixandre M, et al. Synergistic treatment effects with Cerebrolysin and donepezil: results from a randomized, double-blind, multicenter trial to compare safety and efficacy of Cerebrolysin, donepezil and a combination of both in patients with probable Alzheimer’s disease [abstract]. International Conference on Alzheimer’s Disease; 2009 Jul 11–16; Vienna

    10. 10.

      Alvarez XA, Cacabelos R. Integrated clinical study report (protocol EBE031010). A randomized, double-blind, clinical trial to compare the safety and efficacy of a Cerebrolysin and Aricept (donepezil) and a combination therapy in patients with probable Alzheimer’s disease. Unterach, Austria: EBEWE Neuro Pharma GmbH, 2008 Nov 27. (Data on file)

      Google Scholar 

    11. 11.

      Gavrilova SI, Kolykhalov IV, Korovaitseva GI, et al. ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer’s disease [in Russian]. Zh Nevrol Psikhiatr Im SS Korsakova 2005; 105(4): 27–34

      CAS  Google Scholar 

    12. 12.

      Guekht A, Moessler H, Doppler E, et al. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial [abstract plus poster]. 9th International Conference for Alzheimer’s and Parkinson’s Disease; 2009 Mar 11–15; Prague

    13. 13.

      Gusev EI. Integrated clinical study report (protocol EBE-RU-051201). A randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with vascular dementia. Unterach, Austria: EBEWE Neuro Pharma GmbH, 2008 Aug 18. (Data on file)

      Google Scholar 

    14. 14.

      Vereschagin NV, Nekrasova EM, Lebedova NV, et al. Mild forms of multi-infarct dementia: effectiveness of cerebrolysin [in Russian]. Sov Med 1991; (11): 6–8

    15. 15.

      Xiao S, Yan H, Yao P. The efficacy of cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double-blind, placebo-controlled trial. The Cerebrolysin Study Group. Hong Kong J Psychiatry 1999; 9(2): 13–9

      Google Scholar 

    16. 16.

      Muresanu DF. The influence of Cerebrolysin on cognitive performances in patients suffering from vascular dementia. Unterach, Austria: EBEWE Pharmaceuticals Ltd, 1999

      Google Scholar 

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Cerebrolysin®: a guide to its use in dementia. Drugs Ther. Perspect 26, 6–9 (2010). https://doi.org/10.2165/11204240-000000000-00000

    Download citation